The study reveals how drug-tolerant KRAS-mutant cancer cells adapt and how their metabolic vulnerabilities can be targeted (IMAGE)

Chiba University

The study reveals how drug-tolerant KRAS-mutant cancer cells adapt and how their metabolic vulnerabilities can be targeted

Caption

The researchers found that drug-tolerant persister cells (DTPs) survive KRAS inhibition by reshaping their metabolism and becoming dependent on glutamine metabolism and lysosome-associated functions. Targeting these survival mechanisms reduces DTP survival under KRAS inhibition.

Credit

Dr. Shigeki Aoki from Chiba University, Japan Source link: https://doi.org/10.1038/s42003-026-10374-x

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.

License

CC BY-NC-ND

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.